These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17106785)

  • 1. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
    Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
    Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
    Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
    Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
    Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
    Watts NB; Worley K; Solis A; Doyle J; Sheer R
    J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
    Blouin J; Dragomir A; Moride Y; Ste-Marie LG; Fernandes JC; Perreault S
    Br J Clin Pharmacol; 2008 Jul; 66(1):117-27. PubMed ID: 18460036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risedronate prevents hip fractures, but who should get therapy?
    Deal CL
    Cleve Clin J Med; 2002 Dec; 69(12):964, 968-70, 973-6. PubMed ID: 12546269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
    Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
    Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.